Published online before print February 6, 2003, doi: 10.1161/01.RES.0000060700.55247.7C
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2003 American Heart Association, Inc.
Molecular Medicine |
Peroxisome Proliferator-Activated Receptor (PPAR) 
and PPARß/
, but not PPAR
, Modulate the Expression of Genes Involved in Cardiac Lipid Metabolism
From the Department of Physiology (A.J.G., K.A.J.v.d.L., P.H.M.W., G.J.v.d.V., M.v.B.), Cardiovascular Research Institute Maastricht, Maastricht University, the Netherlands; U 545 INSERM, Département d’Athérosclerose (G.C., B.S.), Institut Pasteur de Lille and Faculté de Pharmacie, Université de Lille, France; and Department of Pediatrics (F.R.v.d.L.), Beatrix Children’s Hospital, University of Groningen, the Netherlands.
Correspondence to Dr M. van Bilsen, Department of Physiology, Cardiovascular Research Institute Maastricht, Maastricht University, PO Box 616, 6200 MD Maastricht, the Netherlands. E-mail Marc.vanBilsen{at}FYS.Unimaas.NL
 |
Abstract |
|---|
 Top Abstract IntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Long-chain fatty acids (FA) coordinately induce the expression of a panel of genes involved in cellular FA metabolism in cardiac muscle cells, thereby promoting their own metabolism. These effects are likely to be mediated by peroxisome proliferator-activated receptors (PPARs). Whereas the significance of PPAR
in FA-mediated expression has been demonstrated, the role of the PPARß/
and PPAR
isoforms in cardiac lipid metabolism is unknown. To explore the involvement of each of the PPAR isoforms, neonatal rat cardiomyocytes were exposed to FA or to ligands specific for either PPAR (Wy-14,643), PPARß/ (L-165041, GW501516), or PPAR (ciglitazone and rosiglitazone). Their effect on FA oxidation rate, expression of metabolic genes, and muscle-type carnitine palmitoyltransferase-1 (MCPT-1) promoter activity was determined. Consistent with the PPAR isoform expression pattern, the FA oxidation rate increased in cardiomyocytes exposed to PPAR and PPARß/ ligands, but not to PPAR ligands. Likewise, the FA-mediated expression of FA-handling proteins was mimicked by PPAR and PPARß/, but not by PPAR ligands. As expected, in embryonic rat heart-derived H9c2 cells, which only express PPARß/, the FA-induced expression of genes was mimicked by the PPARß/ ligand only, indicating that FA also act as ligands for the PPARß/ isoform. In cardiomyocytes, MCPT-1 promoter activity was unresponsive to PPAR ligands. However, addition of PPAR and PPARß/ ligands dose-dependently induced promoter activity. Collectively, the present findings demonstrate that, next to PPAR, PPARß/, but not PPAR, plays a prominent role in the regulation of cardiac lipid metabolism, thereby warranting further research into the role of PPARß/ in cardiac disease.
Key Words: cardiomyocytes • H9c2 cells • fatty acids • gene expression • uncoupling protein
|
Introduction |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
It is generally acknowledged that dietary factors, among which are major energy-providing substrates such as fatty acids (FA), act as signaling molecules that modulate gene expression in a variety of tissues, including the heart (for review see Van Bilsen et al1 and Taegtmeyer2). Using primary cultures of neonatal rat cardiomyocytes, it was recently demonstrated that exposure of these cells to long-chain FA markedly enhances the expression of genes encoding proteins involved in FA transport and metabolism.3,4 In addition, evidence was provided that the modulating effect of FA is mediated by peroxisome proliferator-activated receptors (PPARs).3,4 Of the three PPAR isoforms known to date, the significance of PPAR
and PPAR in the regulation of whole-body and cellular lipid metabolism has been firmly established (reviewed in Schoonjans et al5). The function of the ubiquitously expressed PPARß/ isoform, however, remains largely elusive.
Through the development of specific synthetic ligands for PPAR,6 PPAR,7 and more recently for PPARß/,8,9 powerful tools have become available to delineate the biological roles of each of the PPAR isoforms in more detail. This prompted us to investigate the specific roles of PPAR, PPARß/, and PPAR in the cardiac muscle cell with respect to the regulation of genes encoding proteins involved in energy metabolism. Thereto, neonatal rat cardiomyocytes as well as the embryonic rat heart-derived H9c2 cells were cultured in defined medium in the absence or presence of FA. To fully appreciate the role of each of the three PPAR isoforms, their expression pattern was assessed in cardiac cells and H9c2 myoblasts and myotubes. Next, we examined whether specific ligands for PPAR (Wy-14,643), PPARß/ (L-165041, GW501516), and PPAR (ciglitazone and rosiglitazone) were able to mimic the modulating effect of FA on metabolic gene expression in these cell models. Accordingly, their effects on the expression of various proteins involved in cardiac FA metabolism, such as acyl-coenzyme A synthetase (ACS), muscle-type carnitine palmitoyltransferase-1 (MCPT-1), long-chain acyl-coenzyme A dehydrogenase (LCAD), and the uncoupling proteins 2 and 3 (UCP-2/-3) were determined at the mRNA level. To assess the functional consequences of PPAR-mediated transcription on cellular lipid metabolism, FA oxidation rates were measured. For comparison, mRNA levels of proteins involved in glucose transport (GLUT4) and metabolism (hexokinase II [HKII]) were determined. Finally, the effect of the isoform-specific PPAR ligands was explored further in transient transfection studies using the PPAR-responsive human MCPT-1 promoter.3
The collective data indicate that, besides PPAR, the PPARß/ isoform is involved in regulation of cardiac lipid metabolism. In contrast, the role of PPAR in this process appears to be insignificant.
|
Materials and Methods |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Cell Culture
Neonatal rat ventricular cardiomyocytes were prepared as described previously.10 Experiments were approved by the Institutional Animal Care and Use Committee of the Maastricht University.
H9c2 cells (ATCC, Manassas, Va; No. CRL-1446; passage Nos. 18 to 22) were maintained in growth medium composed of DMEM supplemented with 10% fetal bovine serum (Life Technologies). H9c2 cells were plated at a density of 2000 cells/cm2 and allowed to proliferate in growth medium. Medium was changed twice a week. To induce differentiation of H9c2 myoblasts into myotubes, growth medium was replaced with differentiation medium (DMEM containing 2% horse serum) when cells had reached near confluence. The extent of differentiation of the H9c2 cells was evaluated on the basis of morphological criteria and by measuring cellular creatine kinase activity. Cells were considered differentiated after formation of multinucleated myotubes and a >10-fold increase in creatine kinase activity.
At the start of the experiments, H9c2 myoblasts (at near confluence), H9c2 myotubes, and neonatal cardiomyocytes were incubated in serum-free medium consisting of a 4:1 mixture of DMEM/M199, gentamicin (50 mg/L), and glucose (10 mmol/L) as the sole substrate, for 24 hours. Subsequently, the cells were rinsed once with serum-free medium, whereupon experimental medium was applied to the cells. The experimental medium consisted of serum-free medium enriched with 0.25 mmol/L L-carnitine, 0.25 mU/mL insulin, and 0.15 mmol/L BSA (A-7906, Sigma). When indicated, the medium was further supplemented with FA (palmitic and oleic acids 0.25 mmol/L, each complexed to 0.15 mmol/L BSA, as described elsewhere10). To test the effects of PPAR-specific ligands, cells receiving glucose as the only substrate were incubated with the PPAR-ligand Wy-14,643 (reported EC50=0.63 µmol/L7, Biomol), the PPARß/ ligands L-165041 (a gift from Dr J. Berger, Merck Research Laboratories, Rahway, NJ) and GW501516 (EC50=3.8 and 0.024 µmol/L, respectively),7,9 or the PPAR-ligands ciglitazone (Biomol) and rosiglitazone (BRL49653, kindly provided by Glaxo SmithKline) (EC50=3.0 and 0.076 µmol/L, respectively7), at the indicated concentrations (see Results). For detailed information regarding the potency and selectivity of the various ligands for the three PPAR isoforms, we refer to Willson et al7 and Oliver et al.9 PPAR ligands were dissolved in DMSO, which was also added as vehicle (0.1% vol/vol) to control cells.
Tissues and Cells
Hearts and epididymal white adipose tissue were dissected from neonatal and adult Lewis rats. To determine the presence of PPAR isoforms in cardiac myocytes, the myocyte fraction was isolated from neonatal and adult hearts after collagenase treatment by Percoll-gradient centrifugation10 and sedimentation,11 respectively. Tissues and cell fractions were immediately frozen in liquid nitrogen and stored at -80°C until analysis.
RNA Analysis
After 48 hours of incubation, RNA was isolated with TRIzol reagent (Life Technologies). Total RNA (10 µg) was size-fractionated, transferred to nylon membranes, and probed with cDNA fragments of GLUT4, HKII, ACS, LCAD, MCPT-1, UCP-2, and UCP-3 as described previously.4,12,13 A 0.9-kb PstI fragment of mouse PPAR, a 1.5-kb BamHI fragment of rat PPARß/ (a gift of Dr P.A. Grimaldi, University of Nice, France), and a 0.6-kb BglII fragment of hamster PPAR were also used for hybridization. The cDNA probes were labeled with [32P]dCTP (3000 Ci/mmol; Amersham Pharmacia Biotech) by random priming (Radprime, Life Technologies) to a specific activity of >0.5x109 cpm/µg DNA. To correct for possible differences in transfer and loading, the membranes were also hybridized with a 32P-labeled ribosomal 18S probe. After hybridization, membranes were washed at the appropriate stringency to remove nonspecific binding. The membranes were exposed to imaging screens and subsequently scanned on the Personal FX Imager (Bio-Rad Laboratories). Signals were quantified using Quantity One software (Bio-Rad).
Protein Extraction and Western Blot
Tissues and cells were homogenized in lysis buffer (in mmol/L, Tris-HCl 10, NaCl 150, and EDTA 1; 0.1% NP-40; 0.5% sodium deoxycholate; 1% SDS; and a protease inhibitor cocktail), and proteins were collected by centrifugation at 4°C. Proteins (100 µg) were loaded onto 10% SDS-PAGE gels. Ponceau’s red staining was performed to verify equal loading. Western blot analysis was performed using a monoclonal antibody against PPAR (Santa Cruz Biotechnology, Inc) or against -actinin (Sigma). Specific signals were visualized using the enhanced chemiluminescence system (Amersham).
Transient Transfection
For transient transfection, neonatal cardiomyocytes were seeded on 6-well plates at a density of 2.5x105 cells in 2 mL of medium per well. Cells were transfected 16 hours before addition of experimental medium using the transfection reagent FuGENE 6 (Roche). Cells were transfected with 0.5 µg of promoter/reporter vector, ie, a 1.3-kb fragment of the human MCPT-1 promoter generated by high-fidelity polymerase chain reaction (PCR; Expand, Roche) of genomic DNA (corresponding to positions 61203 to 62543; GenBank accession No. U6231714) and cloned into the pGL3 luciferase vector (MCPT-1-luc), or a construct containing three copies of the PPRE site of the human apolipoprotein A-II promoter (PPRE3-TK-luc).15 The cytomegalovirus ß-galactosidase–containing vector pON249 (0.25 µg) was cotransfected to control for transfection efficiency.16 In a subseries of experiments, 0.5 µg of the pSG5 expression vector containing the cDNA of PPAR17 was cotransfected. The total amount of plasmid DNA per well was always kept constant by adding empty pSG5 vector (Promega).
Cells were harvested 24 hours after addition of experimental medium (see above) and immediately processed for the determination of reporter activity. Luciferase activity was determined using a commercial firefly luciferase assay according to the supplier’s instructions (Steady Glo, Promega) in white 96-well plates (Nalge Nunc International) and FluorS imager (Bio-Rad) for measuring luminescence. ß-Galactosidase activity was determined spectrophotometrically (Titertek Multiskan Plus MKII, Thermo LabSystems) as described previously.16
FA Oxidation
Experiments to determine the oxidation capacity of [1-14C]palmitic acid (Amersham) in neonatal rat ventricular cardiomyocytes were performed according to van der Lee et al.4
Statistics
Results are obtained from at least three independent experiments and presented as sample mean±SD. Comparison between groups was performed with one-way ANOVA. In cases in which the F ratio obtained indicated that significant differences between groups were present, a two-tailed Student’s t test for unpaired data was carried out, applying a Bonferroni adjustment for multiple comparison.18 Differences were considered significant at P<0.05.
|
Results |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
FA Supplementation and Gene Expression
To assess the effects of FA on gene expression, neonatal rat cardiomyocytes and myoblasts and myotubes of the embryonic rat heart-derived H9c2 cell line were cultured in the presence of either glucose or a combination of glucose and FA (palmitic and oleic acid) as substrates.
Cardiomyocytes
Consistent with previous studies,4 48 hours after exposure to FA, mRNA levels of the glucose transporter GLUT4 and the glycolytic enzyme HKII were lower (Figure 1A). In contrast, the mRNA levels of ACS, LCAD, and the uncoupling protein UCP-2 were markedly increased.
|
H9c2 Cells
The differentiation of H9c2 myoblasts into myotubes was associated with a rise in the mRNA levels of proteins involved in both glucose (GLUT4 and HKII) and FA (ACS and LCAD) metabolism, but still the mRNA levels were substantially lower than those in cardiomyocytes exposed to identical conditions (data not shown). Likewise, the FA-induced changes in gene expression were less pronounced in the H9c2 cells, reaching statistical significance for HKII, LCAD, and UCP-2 in the myoblasts (Figure 1B), and for GLUT4, HKII, ACS, LCAD as well as UCP-2 in the myotubes, respectively (Figure 1C).
PPAR Isoform Expression
As shown in Figure 1, the effects of FA on gene expression are more pronounced in cardiac myocytes than in H9c2 cells. As the effects of FA on cardiac myocytes are considered to be PPAR mediated,3,4 we first looked for possible differences in PPAR isoform expression or abundance. Thereto, mRNA levels of the PPAR isoforms were determined in the different cell types and in ventricular tissue of neonatal and adult rats (Figure 2). In H9c2 myoblasts and myotubes, as well as in cardiac myocytes and ventricular tissue, PPARß/ was abundantly expressed. Interestingly, PPAR mRNA was not detectable in H9c2 cells but was clearly present in isolated cardiomyocytes and cardiac tissue. In contrast to its preponderance in white adipose tissue, a clear PPAR mRNA signal was not detected either in H9c2 cells, in isolated cardiomyocytes, or in intact ventricular tissue. As the presence of PPAR in cardiac myocytes is controversial,19,20 we also applied Western blotting to further check for the possible presence of this isoform in neonatal and adult cardiac myocytes. PPAR immunoreactivity was readily observed in white adipose tissue, whereas substantially longer exposure times were required to detect signals in cardiac tissue and cardiomyocytes (Figure 3). Collectively these findings demonstrate that the PPAR isoforms are all present in cardiac muscle cells, albeit that -isoform is expressed at relatively low levels.
|
|
Effects of Isoform-Specific PPAR Agonists
Next, the involvement of each of the PPAR isoforms in the FA-mediated changes in gene expression was assessed functionally. Thereto, cardiomyocytes and H9c2 cells were treated with Wy-14,643, L-165041, and ciglitazone, specific agonists for PPAR, PPARß/, and PPAR, respectively. At concentrations of 10 µmol/L, these PPAR agonists were previously shown to be effective and isoform specific in other cell types.6–8
Cardiomyocytes
As shown in Figure 4, none of the PPAR ligands significantly affected the expression of genes involved in glucose uptake (GLUT4) and metabolism (HKII). In contrast, the PPAR-specific ligand Wy-14,643 was as effective as FA in inducing the expression of the FA-handling proteins ACS, MCPT-1, LCAD, and UCP-2 in cardiomyocytes. The addition of the PPARß/ agonist L-165041 also led to an increase, albeit less pronounced, in the mRNA levels of ACS, MCPT-1, and UCP-2.
|
H9c2 Cells
In accordance with the expression pattern of the PPAR isoforms in H9c2 myoblasts and myotubes, the PPAR- and PPAR-specific ligands were ineffective (Figure 5). In contrast, the PPARß/ ligand L-165041 increased mRNA levels of both ACS and LCAD in H9c2 cells to the same degree as FA. Likewise, UCP-2 mRNA levels were clearly upregulated by both FA and L-165041 in H9c2 myoblasts. Conversely, although mRNA of UCP-3 could not be detected in H9c2 myoblasts, in H9c2 myotubes UCP-3 expression was markedly induced by both FA and the PPARß/ agonist. Interestingly, the PPAR ligands did not affect GLUT4 and HKII mRNA levels in myotubes, but exposure to FA was associated with a decline, which suggests that FA also exert PPAR-independent effects.
|
PPAR Isoform-Specific Transcriptional Activation
To demonstrate the PPAR isoform-specific response of neonatal cardiomyocytes, transient transfection was applied. Thereto, the dose response to the various isoform-specific ligands was investigated using the human muscle-type CPT-1 promoter containing a functional PPAR-responsive element3 (Figure 6). The PPAR ligand Wy-14,643 as well as the PPARß/ ligands L-165041 and GW501516 dose-dependently induced promoter activity. For each ligand at 
5 µmol/L, the response reached maximal values, but the level of induction was still lower than that with FA (3.5±1.0-fold). The PPARß/ ligand GW501516 proved to be the most potent ligand used and significantly increased MCPT-1 promoter activity at 10 nmol/L already. The specific PPAR ligands ciglitazone and rosiglitazone, however, were unable to induce MCPT-1 promoter activity, irrespective of the dose applied. The forced overexpression of PPAR substantially increased basal and rosiglitazone-activated transcription activity of both the MCPT-1 promoter (Figure 7A) and a minimal promoter construct containing three copies of the apolipoprotein A-II PPRE (PPRE3-TK-Luc) (Figure 7B), thereby demonstrating the potential of PPAR to regulate transcription in the cardiomyocyte context, provided that PPAR is expressed at high levels.
|
), PPARß/
) and GW501516 (
), and PPAR
) and rosiglitazone (
), respectively. Cells were transiently transfected with the MCPT-1 promoter/luciferase reporter vector and were subsequently treated with the different ligands. Results are expressed as fold induction compared with control (no ligand), which was arbitrarily set 1.0.
|
PPAR Isoforms and FA Oxidation
To test whether the PPAR-mediated changes at the mRNA level were associated with functional alterations in FA metabolism, the effects of the isoform-specific ligands on palmitate oxidation rate were determined (Figure 8). In line with the mRNA data, 14CO2 production from palmitate increased in cardiomyocytes pretreated with the PPAR ligand Wy-14,643 and the PPARß/ ligands L-165041 and GW501516, the latter being more potent. In contrast, the PPAR ligands ciglitazone and rosiglitazone were both ineffective.
|
|
Discussion |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
The present findings demonstrate for the first time that the long-chain FA-induced increase in the expression of genes in cardiac muscle cells is mediated not only by PPAR
, but also by PPARß/. With the use of a panel of PPAR isoform-specific ligands, it is demonstrated that in neonatal cardiomyocytes PPAR and PPARß/, but not PPAR, selectively increase the expression of genes involved in cardiac FA metabolism. The transient transfection studies with the MCPT-1 promoter indicate that these effects are mediated at the transcriptional level. As a consequence, the FA oxidation rate in cardiomyocytes was shown to be enhanced. The fact that in H9c2 cells, which only express the PPARß/ isoform, the effects of FA can only be reproduced by the PPAR ß/-specific ligand further substantiates the notion that FA act as endogenous ligands for PPARß/ in the cardiac muscle context.
PPAR and Cardiomyocyte Gene Expression
Whereas the presence of PPAR and PPARß/ in cardiac tissue has been firmly established,21,22 the presence of PPAR is controversial. PPAR mRNA either was detected at low levels17,22–24 or could not be detected at all in the intact heart.19,25 Recently, however, Takano et al20 demonstrated the presence of PPAR mRNA and immunoreactivity in primary cultures of neonatal rat cardiomyocytes. In the present study, PPAR mRNA appeared to be undetectable by Northern blotting but was detectable using a more sensitive method such as RT-PCR (data not shown) in freshly isolated neonatal and adult cardiomyocytes. Moreover, PPAR immunoreactivity was detectable, albeit weak, revealing small amounts of PPAR protein in cardiac myocytes and tissue. Our results corroborate the findings of Escher et al,24 who showed by quantitative RT-PCR that in the adult heart the mRNA content of PPAR was low as compared with that of PPAR and PPARß/.
The absence of significant effects of the PPAR ligands ciglitazone and rosiglitazone on mRNA levels of all genes investigated, MCPT-1 promoter activity, and cellular FA oxidation rate argues against a role for PPAR in the regulation of cardiac lipid metabolism. Even FAT/CD36, a gene that has convincingly been shown to behave as a PPAR target gene in macrophages,26 did not respond to PPAR ligands in neonatal cardiomyocytes (authors’ unpublished observation, 2001). As the forced overexpression of PPAR in cardiomyocytes is accompanied by basal and ligand-activated transcription of the MCPT-1 promoter, it is conceivable that the virtual absence of PPAR-mediated effects on FA metabolism resides in its low abundance in this cell type.
Other studies, however, revealed effects of PPAR ligands on cardiomyocyte and skeletal muscle cell function and phenotype. In skeletal muscle the stimulatory effects of the glitazones on mitochondrial fuel oxidation were demonstrated to be independent of PPAR-mediated gene expression, suggesting that the drugs exerted PPAR-independent effects.27 Indeed, other signaling pathways, among which is the nuclear factor-
B pathway, have been shown to be modulated by PPAR ligands, involving both PPAR-dependent and PPAR-independent mechanisms.28,29 Collectively, these observations suggest that, notwithstanding the limited relevance of PPAR in cardiac lipid metabolism, a biological role for PPAR in other processes in the heart cannot be dismissed.
Role of PPAR and PPARß/
Both in vitro and in vivo studies demonstrated PPAR to be instrumental in the regulation of the expression of genes coding for proteins involved in cardiac FA metabolism.4,30,31 The present findings with respect to the PPAR isoform expression pattern and the effect of the PPAR ligand Wy-14,643 on gene expression and FA oxidation corroborate these earlier observations.
Along with PPAR, the PPARß/ isoform was shown to be present in cardiomyocytes. However, in myoblasts and myotubes of the embryonic heart-derived cell line H9c2, PPARß/ turned out to be the only isoform present. In contrast to the other isoforms, the biological role of PPARß/ has remained largely enigmatic up to now. Interestingly, in H9c2 cells the effects of FA on gene expression was mimicked by the PPARß/ ligand only. This effect was most obvious for the uncoupling proteins. In H9c2 myoblasts, FA and L-165041 induced UCP-2 mRNA levels to a similar extent, whereas in myotubes UCP-3 responded in a similar way. These findings support the notion that FA function as ligands for PPARß/ in these cells and, by inference, in the cardiac muscle cell as well. Indeed, several recent studies are indicative of a role of PPARß/ in cellular lipid metabolism. In skeletal muscle cells, PPARß/ was shown to be the PPAR subtype responsible for the induction of UCP-3 and UCP-2 mRNA.32,33 In cultured brain cells and keratinocytes, the PPARß/-specific ligand L-165041 increased expression of the ACS isoform ACS2 and FAT/CD36, respectively.34,35 Furthermore, Oliver et al9 demonstrated increased transcription of the cholesterol transport protein ABCA1 by the highly specific PPARß/ ligand GW501516 in macrophages.
The current findings indicate that activation of PPARß/ also modulates neonatal cardiomyocyte gene expression. The mRNA and promoter/reporter studies reveal that the human MCPT-1 gene, previously shown to be responsive to PPAR, is equally responsive to the PPARß/-specific ligands L-165041 and GW501516. On the other hand, differences in response to - and ß/-ligands have to be appreciated too, as the rise in endogenous ACS and LCAD mRNA levels is less pronounced with L-165041 than with Wy-14,643 when applied at equimolar doses (see Figures 4 and 5). Whether the differences in response of individual genes to PPAR and PPARß/ ligands are related to the potency of the respective ligands on the one hand or to subtle differences within PPAR-response elements or flanking sequences on the other awaits further investigation. In this respect it is worth mentioning that differences in the consensus PPAR and PPARß/ binding sites have indeed been reported.36
The present findings strongly suggest that PPAR and PPARß/ share similar functions. Indeed, administration of PPARß/ agonists to PPAR-null mice induces peroxisome proliferation in liver,37 a phenomenon formerly exclusively ascribed to PPAR. Similarly, in PPAR-/- mice, the fasting-induced upregulation of several PPAR-responsive genes in liver and heart is attenuated but not completely blunted.30 The latter findings suggest a residual effect, or partial compensation, involving PPARß/. Furthermore, the recent observation by Muoio et al38 that FA oxidation in skeletal muscle of PPAR-/- mice is not impaired also led these investigators to conclude that PPARß/ compensates for the lack of PPAR in these mice.
Taken together, the present findings argue against a significant role for PPAR in the regulation of metabolic gene expression in heart muscle cells. Furthermore, unequivocal evidence is presented that, next to PPAR, PPARß/ is an important regulator of the expression of genes involved in cardiac lipid metabolism. Accordingly, further investigation into the role of PPARß/ isoform in the regulation of cardiac FA homeostasis during cardiac disease is warranted.
|
Acknowledgments |
|---|
This research was funded by grants from the Netherlands Heart Foundation (NHS 1998T015 to M.v.B. and NHS 1997B093 to F.R.v.d.L.), the European Union (QLG1-1999-01007 to G.C.), the Leducq Foundation, and the FEDER/Conseil Régional Nord/Pas-de-Calais (Genopole 01360124 to B.S.). We thank E.M.H. Cuijpers and R.L.M. Lotz for technical support.
|
Footnotes |
|---|
*Both authors contributed equally to this study.
Received June 19, 2002; revision received December 13, 2002; accepted January 29, 2003.
|
References |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
1. Van Bilsen M, van der Vusse GJ, Reneman RS. Transcriptional regulation of metabolic processes: implications for cardiac metabolism. Eur J Physiol. 1998; 437: 2–14.[CrossRef][Medline] [Order article via Infotrieve]
2. Taegtmeyer H. Genetics of energetics: transcriptional responses in cardiac metabolism. Ann Biomed Eng. 2000; 28: 871–876.[CrossRef][Medline] [Order article via Infotrieve]
3. Brandt JM, Djouadi F, Kelly DP. Fatty acids activate transcription of the muscle carnitine palmitoyltransferase I gene in cardiac myocytes via the peroxisome proliferator-activated receptor . J Biol Chem. 1998; 273: 23786–23792.
4. van der Lee KAJM, Vork MM, De Vries JE, Willemsen PHM, Glatz JFC, Reneman RS, Van der Vusse GJ, Van Bilsen M. Long-chain fatty acid-induced changes in gene expression in neonatal cardiac myocytes. J Lipid Res. 2000; 41: 41–47.
5. Schoonjans K, Staels B, Auwerx J. The peroxisome proliferator activated receptors (PPARs) and their effects on lipid metabolism and adipocyte differentiation. Biochim Biophys Acta. 1996; 1302: 93–109.[Medline] [Order article via Infotrieve]
6. Yu K, Bayona W, Kallen CB, Harding HP, Ravera CP, McMahon G, Brown M, Lazar MA. Differential activation of peroxisome proliferator-activated receptors by eicosanoids. J Biol Chem. 1995; 270: 23957–23983.
7. Willson TM, Brown PJ, Sternbach DD, Henke BR. The PPARs: from orphan receptors to drug discovery. J Med Chem. 2000; 43: 527–550.[CrossRef][Medline] [Order article via Infotrieve]
8. Berger J, Leibowitz MD, Doebber TW, Elbrecht A, Zhang B, Zhou G, Biswas C, Cullinan CA, Hayes NS, Li Y, Tanen M, Ventre J, Wu MS, Berger GD, Mosley R, Marquis R, Santini C, Sahoo SP, Tolman RL, Smith RG, Moller DE. Novel peroxisome proliferator-activated receptor (PPAR) and PPAR ligands produce distinct biological effects. J Biol Chem. 1999; 274: 6718–6725.
9. Oliver WR Jr, Shenk JL, Snaith MR, Russell CS, Plunket KD, Bodkin NL, Lewis MC, Winegar DA, Sznaidman ML, Lambert MH, Xu HE, Sternbach DD, Kliewer SA, Hansen BC, Willson TM. A selective peroxisome proliferator-activated receptor agonist promotes reverse cholesterol transport. Proc Natl Acad Sci U S A. 2001; 98: 5306–5311.
10. De Vries JE, Vork MM, Roemen THM, de Jong YF, Cleutjens JPM, Van der Vusse GJ, Van Bilsen M. Saturated but not mono-unsaturated fatty acids induce apoptotic cell death in neonatal rat ventricular myocytes. J Lipid Res. 1997; 38: 1384–1394.[Abstract]
11. Jans SWS, de Jong YF, Reutelingsperger CPM, Van der Vusse GJ, Van Bilsen M. Differential expression and localization of annexin V in cardiac myocytes during growth and hypertrophy. Mol Cell Biochem. 1998; 178: 229–236.[CrossRef][Medline] [Order article via Infotrieve]
12. Van der Lee KAJM, Willemsen PHM, Van der Vusse GJ, Van Bilsen M. Effects of fatty acids on uncoupling protein-2 expression in the rat heart. FASEB J. 2000; 14: 495–502.
13. Van der Lee KAJM, Willemsen PHM, Samec S, Seydoux J, Dulloo AG, Pelsers MMAL, Glatz JFC, Van der Vusse GJ, Van Bilsen M. Fasting-induced changes in the expression of genes controlling substrate metabolism in the rat heart. J Lipid Res. 2001; 42: 1752–1758.
14. van der Leij FR, Takens J, van der Veen AY, Terpstra P, Kuipers JR. Localization and intron usage analysis of the human CPT1B gene for muscle type carnitine palmitoyltransferase I. Biochim Biophys Acta. 1997; 1352: 123–128.[Medline] [Order article via Infotrieve]
15. Vu Dac N, Schoonjans K, Kosykh V, Dallongeville J, Fruchart JC, Staels B, Auwerx J. Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor. J Clin Invest. 1995; 96: 741–750.[Medline] [Order article via Infotrieve]
16. Shubeita HE, Martinson EA, Van Bilsen M, Chien KR, Brown JH. Transcriptional activation of the cardiac myosin light chain 2 and atrial natriuretic factor genes by protein kinase C in neonatal rat ventricular myocytes. Proc Natl Acad Sci U S A. 1992; 89: 1305–1309.
17. Aperlo C, Pognonec P, Saladin R, Auwerx J, Boulukos KE. cDNA cloning and characterization of the transcriptional activities of the hamster peroxisome proliferator-activated receptor haPPAR. Gene. 1995; 162: 297–302.[CrossRef][Medline]
[Order article via Infotrieve]
18. Wallenstein S, Zucker CL, Fleiss JL. Some statistical methods useful in circulation research. Circ Res. 1980; 47: 1–9.
19. Braissant O, Foufelle F, Scotto C, Dauça M, Wahli W. Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR, -ß, and - in the adult rat. Endocrinology. 1996; 137: 354–366.[Abstract]
20. Takano H, Nagai T, Asakawa M, Toyozaki T, Oka T, Komuro I, Saito T, Masuda Y. Peroxisome proliferator-activated receptor activators inhibit lipopolysaccharide-induced tumor necrosis factor- expression in neonatal rat cardiac myocytes. Circ Res. 2000; 87: 596–602.
21. Mukherjee R, Jow L, Noonan D, McDonnell DP. Human and rat peroxisome proliferator activated receptors (PPARs) demonstrate similar tissue distribution but different responsiveness to PPAR activators. J Steroid Biochem Mol Biol. 1994; 51: 157–166.[CrossRef][Medline] [Order article via Infotrieve]
22. Kliewer SA, Forman BM, Blumberg B, Ong ES, Borgmeyer U, Mangelsdorf DJ, Umesono K, Evans RM. Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. Proc Natl Acad Sci U S A. 1994; 91: 7355–7359.
23. Zhu Y, Alvares K, Huang Q, Rao MS, Reddy JK. Cloning of a new member of the peroxisome proliferator-activated receptor gene family from mouse liver. J Biol Chem. 1993; 268: 26817–26820.
24. Escher P, Braissant O, Basu-Modak S, Michalik L, Wahli W, Desvergne B. Rat PPARs: quantitative analysis in adult rat tissues and regulation in fasting and refeeding. Endocrinology. 2001; 142: 4195–4202.
25. Jones PS, Savory R, Barratt P, Bell AR, Gray TJB, Jenkins NA, Gilbert DJ, Copeland NG, Bell DR. Chromosomal localisation, inducibility, tissue-specific expression and strain differences in three murine peroxisome-proliferator-activated-receptor genes. Eur J Biochem. 1995; 233: 219–226.[Medline] [Order article via Infotrieve]
26. Tontonoz P, Nagy L, Alvarez JGA, Thomazy VA, Evans RM. PPAR promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell. 1998; 93: 241–252.[CrossRef][Medline]
[Order article via Infotrieve]
27. Brunmair B, Gras F, Neschen S, Roden M, Wagner L, Waldhausl W, Furnsinn C. Direct thiazolidinedione action on isolated rat skeletal muscle fuel handling is independent of peroxisome proliferator-activated receptor--mediated changes in gene expression. Diabetes. 2001; 50: 2309–2315.
28. Yamamoto K, Ohki R, Lee RT, Ikeda U, Shimada K. Peroxisome proliferator-activated receptor activators inhibit cardiac hypertrophy in cardiac myocytes. Circulation. 2001; 104: 1670–1675.
29. Castrillo A, Díaz-Guerra MJ, Hortelano S, Martín-Sanz P, Boscá L. Inhibition of IB kinase and IB phosphorylation by 15-deoxy-
12,14-prostaglandin J2 in activated murine macrophages. Mol Cell Biol. 2000; 20: 1692–1698.
30. Leone TC, Weinheimer CJ, Kelly DP. A critical role for the peroxisome proliferator-activated receptor (PPAR) in the cellular fasting response: the PPAR-null mouse as a model of fatty acid oxidation disorders. Proc Natl Acad Sci U S A. 1999; 96: 7473–7478.
31. Watanabe K, Fujii H, Takahashi T, Kodama M, Aizawa Y, Ohta Y, Ono T, Hasegawa G, Naito M, Nakajima T, Kamijo Y, Gonzalez FJ, Aoyama T. Constitutive regulation of cardiac fatty acid metabolism through peroxisome proliferator-activated receptor associated with age-dependent cardiac toxicity. J Biol Chem. 2000; 275: 22293–22299.
32. Nagase I, Yoshida S, Canas X, Irie Y, Kimura K, Yoshida T, Saito M. Up-regulation of uncoupling protein 3 by thyroid hormone, peroxisome proliferator-activated receptor ligands and 9-cis retinoic acid in L6 myotubes. FEBS Lett. 1999; 461: 319–322.[CrossRef][Medline] [Order article via Infotrieve]
33. Chevillotte E, Rieusset J, Roques M, Desage M, Vidal H. The regulation of uncoupling protein-2 gene expression by 
-6 polyunsaturated fatty acids in human skeletal muscle cells involves multiple pathways, including the nuclear receptor peroxisome proliferator-activated receptor ß. J Biol Chem. 2001; 276: 10853–10860.
34. Basu-Modak S, Braissant O, Escher P, Desvergne B, Honegger P, Wahli W. Peroxisome proliferator-activated receptor ß regulates acyl-CoA synthetase 2 in reaggregated rat brain cell cultures. J Biol Chem. 1999; 274: 35881–35888.
35. Westergaard M, Henningsen J, Svendsen ML, Johansen C, Jensen UB, Schrøder HD, Kratchmarova I, Berge RK, Iversen L, Bolund L, Kragballe K, Kristiansen K. Modulation of keratinocyte gene expression and differentiation by PPAR-selective ligands and tetradecylthioacetic acid. J Invest Dermatol. 2001; 116: 702–712.[CrossRef][Medline] [Order article via Infotrieve]
36. He TC, Chan TA, Vogelstein B, Kinzler KW. PPAR is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell. 1999; 99: 335–345.[CrossRef][Medline]
[Order article via Infotrieve]
37. DeLuca JG, Doebber TW, Kelly LJ, Kemp RK, Molon-Noblot S, Sahoo SP, Ventre J, Wu MS, Peters JM, Gonzalez FJ, Moller DE. Evidence for peroxisome proliferator-activated receptor (PPAR) -independent peroxisome proliferation: effects of PPAR/-specific agonists in PPAR-null mice. Mol Pharmacol. 2000; 58: 470–476.
38. Muoio DM, MacLean PS, Lang DB, Li S, Houmard JA, Way JM, Winegar DA, Corton JC, Dohm GL, Kraus WE. Fatty acid homeostasis and induction of lipid regulatory genes in skeletal muscles of peroxisome proliferator-activated receptor (PPAR) knock-out mice: evidence for compensatory regulation by PPAR. J Biol Chem. 2002; 277: 26089–26097.
This article has been cited by other articles:
 |
|
 |
|
  E. Ehrenborg and A. Krook Regulation of Skeletal Muscle Physiology and Metabolism by Peroxisome Proliferator-Activated Receptor {delta} Pharmacol. Rev., September 1, 2009; 61(3): 373 - 393. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. D. Hafstad, A. M. Khalid, M. Hagve, T. Lund, T. S. Larsen, D. L. Severson, K. Clarke, R. K. Berge, and E. Aasum Cardiac peroxisome proliferator-activated receptor-{alpha} activation causes increased fatty acid oxidation, reducing efficiency and post-ischaemic functional loss Cardiovasc Res, August 1, 2009; 83(3): 519 - 526. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. van Bilsen, F. A. van Nieuwenhoven, and G. J. van der Vusse Metabolic remodelling of the failing heart: beneficial or detrimental? Cardiovasc Res, February 15, 2009; 81(3): 420 - 428. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. J. H. Smeets, B. E. J. Teunissen, A. Planavila, H. de Vogel-van den Bosch, P. H. M. Willemsen, G. J. van der Vusse, and M. van Bilsen Inflammatory Pathways Are Activated during Cardiomyocyte Hypertrophy and Attenuated by Peroxisome Proliferator-activated Receptors PPAR{alpha} and PPAR{delta} J. Biol. Chem., October 24, 2008; 283(43): 29109 - 29118. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Faiola, J. G. Falls, R. A. Peterson, N. R. Bordelon, T. A. Brodie, C. A. Cummings, E. H. Romach, and R. T. Miller PPAR alpha, more than PPAR delta, Mediates the Hepatic and Skeletal Muscle Alterations Induced by the PPAR Agonist GW0742 Toxicol. Sci., October 1, 2008; 105(2): 384 - 394. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. M. Witteles and M. B. Fowler Reply. J. Am. Coll. Cardiol., July 15, 2008; 52(3): 239 - 240. [Full Text] [PDF]
|
|
|
|
|
|
D. J. Chess and W. C. Stanley Role of diet and fuel overabundance in the development and progression of heart failure Cardiovasc Res, July 15, 2008; 79(2): 269 - 278. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Ventura-Clapier, A. Garnier, and V. Veksler Transcriptional control of mitochondrial biogenesis: the central role of PGC-1{alpha} Cardiovasc Res, July 15, 2008; 79(2): 208 - 217. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T.-L. Yue, S. S. Nerurkar, W. Bao, B. M. Jucker, L. Sarov-Blat, K. Steplewski, E. H. Ohlstein, and R. N. Willette In Vivo Activation of Peroxisome Proliferator-Activated Receptor-{delta} Protects the Heart from Ischemia/Reperfusion Injury in Zucker Fatty Rats J. Pharmacol. Exp. Ther., May 1, 2008; 325(2): 466 - 474. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Gelinas, F. Labarthe, B. Bouchard, J. Mc Duff, G. Charron, M. E. Young, and C. Des Rosiers Alterations in carbohydrate metabolism and its regulation in PPAR{alpha} null mouse hearts Am J Physiol Heart Circ Physiol, April 1, 2008; 294(4): H1571 - H1580. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Montessuit, I. Papageorgiou, and R. Lerch Nuclear Receptor Agonists Improve Insulin Responsiveness in Cultured Cardiomyocytes through Enhanced Signaling and Preserved Cytoskeletal Architecture Endocrinology, March 1, 2008; 149(3): 1064 - 1074. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. M. Witteles and M. B. Fowler Insulin-Resistant Cardiomyopathy: Clinical Evidence, Mechanisms, and Treatment Options J. Am. Coll. Cardiol., January 15, 2008; 51(2): 93 - 102. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Rodriguez-Calvo, L. Serrano, E. Barroso, T. Coll, X. Palomer, A. Camins, R. M. Sanchez, M. Alegret, M. Merlos, M. Pallas, et al. Peroxisome Proliferator-Activated Receptor {alpha} Down-Regulation Is Associated With Enhanced Ceramide Levels in Age-Associated Cardiac Hypertrophy J. Gerontol. A Biol. Sci. Med. Sci., December 1, 2007; 62(12): 1326 - 1336. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. T. Schaiff, F. F. Knapp Jr., Y. Barak, T. Biron-Shental, D. M. Nelson, and Y. Sadovsky Ligand-Activated Peroxisome Proliferator Activated Receptor {gamma} Alters Placental Morphology and Placental Fatty Acid Uptake in Mice Endocrinology, August 1, 2007; 148(8): 3625 - 3634. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. E.J. Teunissen, P. J.H. Smeets, P. H.M. Willemsen, L. J. De Windt, G. J. Van der Vusse, and M. Van Bilsen Activation of PPAR{delta} inhibits cardiac fibroblast proliferation and the transdifferentiation into myofibroblasts Cardiovasc Res, August 1, 2007; 75(3): 519 - 529. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. N. Finck and D. P. Kelly Peroxisome Proliferator-Activated Receptor {gamma} Coactivator-1 (PGC-1) Regulatory Cascade in Cardiac Physiology and Disease Circulation, May 15, 2007; 115(19): 2540 - 2548. [Full Text] [PDF]
|
|
|
|
 |
|
 T.-A. S. Duhaney, L. Cui, M. K. Rude, N. K. Lebrasseur, S. Ngoy, D. S. De Silva, D. A. Siwik, R. Liao, and F. Sam Peroxisome Proliferator-Activated Receptor {alpha}-Independent Actions of Fenofibrate Exacerbates Left Ventricular Dilation and Fibrosis in Chronic Pressure Overload Hypertension, May 1, 2007; 49(5): 1084 - 1094. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Sharma, I. C. Okere, M. K. Duda, D. J. Chess, K. M. O'Shea, and W. C. Stanley Potential impact of carbohydrate and fat intake on pathological left ventricular hypertrophy Cardiovasc Res, January 15, 2007; 73(2): 257 - 268. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. N. Finck The PPAR regulatory system in cardiac physiology and disease Cardiovasc Res, January 15, 2007; 73(2): 269 - 277. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. An and B. Rodrigues Role of changes in cardiac metabolism in development of diabetic cardiomyopathy Am J Physiol Heart Circ Physiol, October 1, 2006; 291(4): H1489 - H1506. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. G. Smith and G. E. O. Muscat Orphan nuclear receptors: therapeutic opportunities in skeletal muscle Am J Physiol Cell Physiol, August 1, 2006; 291(2): C203 - C217. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. Murray, C. A. Lygate, M. A. Cole, C. A. Carr, G. K. Radda, S. Neubauer, and K. Clarke Insulin resistance, abnormal energy metabolism and increased ischemic damage in the chronically infarcted rat heart Cardiovasc Res, July 1, 2006; 71(1): 149 - 157. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. R. Benton, D. P. Y. Koonen, J. Calles-Escandon, N. N. Tandon, J. F. C. Glatz, J. J. F. P. Luiken, J. J. Heikkila, and A. Bonen Differential effects of contraction and PPAR agonists on the expression of fatty acid transporters in rat skeletal muscle J. Physiol., May 15, 2006; 573(1): 199 - 210. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Xu, L. Lu, C. Greyson, M. Rizeq, K. Nunley, B. Wyatt, M. R. Bristow, C. S. Long, and G. G. Schwartz The PPAR-{alpha} activator fenofibrate fails to provide myocardial protection in ischemia and reperfusion in pigs Am J Physiol Heart Circ Physiol, May 1, 2006; 290(5): H1798 - H1807. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. E. Morgan, J. H. Rennison, M. E. Young, T. A. McElfresh, T. A. Kung, K.-Y. Tserng, B. D. Hoit, W. C. Stanley, and M. P. Chandler Effects of chronic activation of peroxisome proliferator-activated receptor-{alpha} or high-fat feeding in a rat infarct model of heart failure Am J Physiol Heart Circ Physiol, May 1, 2006; 290(5): H1899 - H1904. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Verreth, J. Ganame, A. Mertens, H. Bernar, M.-C. Herregods, and P. Holvoet Peroxisome Proliferator-Activated Receptor-{alpha},{gamma}-Agonist Improves Insulin Sensitivity and Prevents Loss of Left Ventricular Function in Obese Dyslipidemic Mice Arterioscler Thromb Vasc Biol, April 1, 2006; 26(4): 922 - 928. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Pesant, S. Sueur, P. Dutartre, M. Tallandier, P. A. Grimaldi, L. Rochette, and J.-L. Connat Peroxisome proliferator-activated receptor {delta} (PPAR{delta}) activation protects H9c2 cardiomyoblasts from oxidative stress-induced apoptosis Cardiovasc Res, February 1, 2006; 69(2): 440 - 449. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Benkirane, F. Amiri, Q. N. Diep, M. El Mabrouk, and E. L. Schiffrin PPAR-{gamma} inhibits ANG II-induced cell growth via SHIP2 and 4E-BP1 Am J Physiol Heart Circ Physiol, January 1, 2006; 290(1): H390 - H397. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. J. Murray, M. Panagia, D. Hauton, G. F. Gibbons, and K. Clarke Plasma Free Fatty Acids and Peroxisome Proliferator-Activated Receptor {alpha} in the Control of Myocardial Uncoupling Protein Levels Diabetes, December 1, 2005; 54(12): 3496 - 3502. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. C. Stanley, F. A. Recchia, and G. D. Lopaschuk Myocardial Substrate Metabolism in the Normal and Failing Heart Physiol Rev, July 1, 2005; 85(3): 1093 - 1129. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Zhang, A. Zhang, D. E. Kohan, R. D. Nelson, F. J. Gonzalez, and T. Yang Collecting duct-specific deletion of peroxisome proliferator-activated receptor {gamma} blocks thiazolidinedione-induced fluid retention PNAS, June 28, 2005; 102(26): 9406 - 9411. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. L. M. Coort, W. A. Coumans, A. Bonen, G. J. van der Vusse, J. F. C. Glatz, and J. J. F. P. Luiken Divergent effects of rosiglitazone on protein-mediated fatty acid uptake in adipose and in muscle tissues of Zucker rats J. Lipid Res., June 1, 2005; 46(6): 1295 - 1302. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Planavila, J. C. Laguna, and M. Vazquez-Carrera Nuclear Factor-{kappa}B Activation Leads to Down-regulation of Fatty Acid Oxidation during Cardiac Hypertrophy J. Biol. Chem., April 29, 2005; 280(17): 17464 - 17471. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. K. Kramer, L. Al-Khalili, S. Perrini, J. Skogsberg, P. Wretenberg, K. Kannisto, H. Wallberg-Henriksson, E. Ehrenborg, J. R. Zierath, and A. Krook Direct Activation of Glucose Transport in Primary Human Myotubes After Activation of Peroxisome Proliferator-Activated Receptor {delta} Diabetes, April 1, 2005; 54(4): 1157 - 1163. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. N. Petrashevskaya and A. Schwarz Peroxisome proliferator-activated receptor {beta}/{delta}: a new antihypertrophic drug target? Cardiovasc Res, March 1, 2005; 65(4): 770 - 771. [Full Text] [PDF]
|
|
|
|
|
|
A. Planavila, R. Rodriguez-Calvo, M. Jove, L. Michalik, W. Wahli, J. C. Laguna, and M. Vazquez-Carrera Peroxisome proliferator-activated receptor {beta}/{delta} activation inhibits hypertrophy in neonatal rat cardiomyocytes Cardiovasc Res, March 1, 2005; 65(4): 832 - 841. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. L. Schiffrin Peroxisome proliferator-activated receptors and cardiovascular remodeling Am J Physiol Heart Circ Physiol, March 1, 2005; 288(3): H1037 - H1043. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. N. Lavrentyev, D. He, and G. A. Cook Expression of genes participating in regulation of fatty acid and glucose utilization and energy metabolism in developing rat hearts Am J Physiol Heart Circ Physiol, November 1, 2004; 287(5): H2035 - H2042. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Huss and D. P. Kelly Nuclear Receptor Signaling and Cardiac Energetics Circ. Res., September 17, 2004; 95(6): 568 - 578. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Bartelds, J. Takens, G. B. Smid, V. A. Zammit, C. Prip-Buus, J. R. G. Kuipers, and F. R. van der Leij Myocardial carnitine palmitoyltransferase I expression and long-chain fatty acid oxidation in fetal and newborn lambs Am J Physiol Heart Circ Physiol, June 1, 2004; 286(6): H2243 - H2248. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Marx, H. Duez, J.-C. Fruchart, and B. Staels Peroxisome Proliferator-Activated Receptors and Atherogenesis: Regulators of Gene Expression in Vascular Cells Circ. Res., May 14, 2004; 94(9): 1168 - 1178. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. N. Carley, L. M. Semeniuk, Y. Shimoni, E. Aasum, T. S. Larsen, J. P. Berger, and D. L. Severson Treatment of type 2 diabetic db/db mice with a novel PPAR{gamma} agonist improves cardiac metabolism but not contractile function Am J Physiol Endocrinol Metab, March 1, 2004; 286(3): E449 - E455. [Abstract] [Full Text]
|
|
|
|
|
|
K. Feingold, M. S. Kim, J. Shigenaga, A. Moser, and C. Grunfeld Altered expression of nuclear hormone receptors and coactivators in mouse heart during the acute-phase response Am J Physiol Endocrinol Metab, February 1, 2004; 286(2): E201 - E207. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. van Bilsen, P. J.H Smeets, A. J Gilde, and G. J van der Vusse Metabolic remodelling of the failing heart: the cardiac burn-out syndrome? Cardiovasc Res, February 1, 2004; 61(2): 218 - 226. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U. Dressel, T. L. Allen, J. B. Pippal, P. R. Rohde, P. Lau, and G. E. O. Muscat The Peroxisome Proliferator-Activated Receptor {beta}/{delta} Agonist, GW501516, Regulates the Expression of Genes Involved in Lipid Catabolism and Energy Uncoupling in Skeletal Muscle Cells Mol. Endocrinol., December 1, 2003; 17(12): 2477 - 2493. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. P. Russell, J. Feilchenfeldt, S. Schreiber, M. Praz, A. Crettenand, C. Gobelet, C. A. Meier, D. R. Bell, A. Kralli, J.-P. Giacobino, et al. Endurance Training in Humans Leads to Fiber Type-Specific Increases in Levels of Peroxisome Proliferator-Activated Receptor-{gamma} Coactivator-1 and Peroxisome Proliferator-Activated Receptor-{alpha} in Skeletal Muscle Diabetes, December 1, 2003; 52(12): 2874 - 2881. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Iglarz, R. M. Touyz, E. C. Viel, P. Paradis, F. Amiri, Q. N. Diep, and E. L. Schiffrin Peroxisome Proliferator-Activated Receptor-{alpha} and Receptor-{gamma} Activators Prevent Cardiac Fibrosis in Mineralocorticoid-Dependent Hypertension Hypertension, October 1, 2003; 42(4): 737 - 743. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. L. Schiffrin, F. Amiri, K. Benkirane, M. Iglarz, and Q. N. Diep Peroxisome Proliferator-Activated Receptors: Vascular and Cardiac Effects in Hypertension Hypertension, October 1, 2003; 42(4): 664 - 668. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. P. Kelly PPARs of the Heart: Three Is a Crowd Circ. Res., March 21, 2003; 92(5): 482 - 484. [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||